Dr. Mojgan Jalalzadeh, MD

Dr. Jalalzadeh practices at Robert Wood Johnson University Hospital in New Brunswick, New Jersey, part of RWJBarnabas Health.

Dr. Jalalzadeh's NPI, 1902335961, was assigned on June 5, 2017. Dr. Jalalzadeh holds Texas license V3331.

Dr. Jalalzadeh's primary practice is Robert Wood Johnson University Hospital, at One Robert Wood Johnson Place, New Brunswick, NJ 08901 in Middlesex County. The practice phone is (732) 828-3000. Dr. Jalalzadeh also practices at Robert Wood Johnson University Hospital - New Brunswick, 1 Robert Wood Johnson Pl, New Brunswick, NJ 08901.

Dr. Jalalzadeh's primary practice is Robert Wood Johnson University Hospital in New Brunswick, New Jersey, part of RWJBarnabas Health. Dr. Jalalzadeh is also affiliated with Baylor Scott & White Medical Center - Temple. The medical group on file is Rutgers Robert Wood Johnson Medical Group. Dmand AI also links Dr. Jalalzadeh to 1 more hospital, 3 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jalalzadeh practices, 4 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Jalalzadeh's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Jalalzadeh is licensed in Texas.

CMS data shows 446 Medicare services from Dr. Jalalzadeh across 7 procedure codes in 2024, for 171 Medicare patients. Medicare paid $39,166 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 171 Medicare patients who saw Dr. Jalalzadeh in 2024. The largest group is under 65, with 108 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 57% are also on Medicaid. Their average risk score is 5.89, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Jalalzadeh's median patient age at 60, with 37% women.

In 2024, Dr. Jalalzadeh wrote 110 Medicare Part D claims for 37 patients. 83% of them were for generic drugs. CMS names the drug for 28 of them, across 2 drugs with 11 or more claims each, at $169 in total drug cost. In 2023, CMS named 192 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Jalalzadeh for performance year 2024, reported as part of a group.

Dmand AI links 18 papers to Dr. Jalalzadeh, published from 2012 to 2021. 2021 was the busiest year, with 4. The most frequent topics are Kidney Failure, Chronic, Kidney Transplantation and Postoperative Complications. Dr. Jalalzadeh has published most often in Cureus. Dr. Jalalzadeh's most frequent co-authors are Donald Irving Baumstein, MD and Armeen Poor.

CMS Open Payments shows 3 general payments to Dr. Jalalzadeh from 3 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 100% of the total. Eurofins Viracor, LLC paid the most, $100.